Trial Profile
Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Ataxia
- Focus Pharmacodynamics
- Acronyms 4AP in EA2
- 12 Nov 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 07 Feb 2014 Planned end date changed from 1 Apr 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 07 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.